Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.88B P/E - EPS this Y 26.10% Ern Qtrly Grth -
Income -483.04M Forward P/E -2.87 EPS next Y -11.20% 50D Avg Chg -38.00%
Sales 78.88M PEG -0.31 EPS past 5Y - 200D Avg Chg -43.00%
Dividend N/A Price/Book 0.95 EPS next 5Y 7.00% 52W High Chg -55.00%
Recommedations 2.20 Quick Ratio 12.01 Shares Outstanding 136.64M 52W Low Chg 12.00%
Insider Own 11.44% ROA -16.55% Shares Float 91.53M Beta 0.46
Inst Own 75.13% ROE -29.78% Shares Shorted/Prior 5.97M/5.63M Price 14.04
Gross Margin - Profit Margin - Avg. Volume 1,171,953 Target Price 33.86
Oper. Margin -4,304.23% Earnings Date Oct 31 Volume 673,389 Change -1.40%
About Vir Biotechnology, Inc.

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Vir Biotechnology, Inc. News
12/18/24 Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
12/12/24 Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
12/03/24 Janux Catapults 49% On 'Unprecedented' Results In Prostate Cancer; Vir Goes For A Ride
12/01/24 Will Vir Biotechnology (NASDAQ:VIR) Spend Its Cash Wisely?
11/26/24 Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs
09:30 AM Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference
11/18/24 Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program
11/18/24 Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency
11/15/24 What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday?
11/15/24 Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting
11/04/24 Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results
11/02/24 Vir Biotechnology Third Quarter 2024 Earnings: Misses Expectations
11/01/24 Vir Biotechnology Inc (VIR) Q3 2024 Earnings Call Highlights: Strategic Restructuring and ...
11/01/24 Vir Biotechnology (NASDAQ:VIR) shareholders have endured a 76% loss from investing in the stock three years ago
10/31/24 U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners
10/31/24 Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Lags Revenue Estimates
10/31/24 Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
10/18/24 State Street Corp's Strategic Acquisition in Vir Biotechnology Inc
10/17/24 Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024
10/15/24 Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD’s The Liver Meeting® 2024
VIR Chatroom

User Image Dunnieboy1 Posted - 12 hours ago

$VIR we never got the ’santa rally’ but i believe 2025 will be an amazing year for Vir, based on positive results for our cancer trials which will bridge us in to the Hepatitis functional cure data due out Q2 and we will have also begun the phase 3 registrational trials in early 2025. If the results are good it will truly be the ’transformational year’ we want in terms of the ‘share price’. All the best to fellow Vir shareholders in 2025 and every year for that matter.

User Image SouthHaus Posted - 1 day ago

$VIR Just bought a batch. Happy Holidays, y’all!

User Image chasemac030586 Posted - 1 day ago

$VIR https://www.wosu.org/npr-news/2024-12-12/this-drug-is-the-breakthrough-of-the-year-and-it-could-mean-the-end-of-the-hiv-epidemic Diminishes VIR HIV pipeline? Or brings additional interest and investment to HIV treatment and prevention drugs?

User Image ONOL Posted - 6 days ago

$VIR when are de going to have FDA fast track answer? It was posted on the 26th June 2024.,,

User Image Dunnieboy1 Posted - 6 days ago

$VIR Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference 12/18/2024 DOWNLOAD(OPENS IN NEW WINDOW) SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, at 4:30 p.m. PT in San Francisco, California. A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website at www.vir.bio and will be archived there for 30 days.

User Image Dunnieboy1 Posted - 1 week ago

$VIR we got a rise yesterday albeit a small one certainly better than a down day, lets hope we can continue today. We have 4 catalysts in the new year, 2 of our cancer trials are reporting on Jan 8 a third cancer trial is beginning in January & we have phase 3 trials for Hepatitis beginning in Q1 2025. Hepatitis data being reported in Q2 2025. We were promised a ’transformational year’ last year & to some extent received it with our move to Cancer treatments, but it would be nice if the share price started reflecting the potential of Vir who’s market cap is only reflective of the cash & investments we hold, at one time the market would assign some ‘enterprise value‘ to a company but not one iota is attached to Vir’s ’blossoming‘ pipeline.

User Image Dunnieboy1 Posted - 1 week ago

$VIR A Santa Rally is stock market phenomenon where equities across developed markets see a short-term positive effect around Christmas. Many analysts think that a rise qualifies as a Santa Rally if it gets going in the week before Christmas, with the effect ending around the start of January. Any rally would do😂

User Image mikebiotechstonks Posted - 1 week ago

$VIR added on weakness

User Image Biotech_Beast Posted - 1 week ago

$VIR has a few T-cell engagers with potential in oncology, in addition to its hepatitis drugs. https://seekingalpha.com/article/4744176-vir-biotechnology-could-be-an-early-riser-in-2025-with-oncology-data-in-january

User Image Dunnieboy1 Posted - 1 week ago

$VIR a few things i’m wondering one is the amount of shares held by institutions(75.3%) & insiders(12%) killing the market, with little stock available market makers will lose interest in a stock, seen this years ago with a company called Matalan the family who owned Matalan held 85% of the shares so there was no liquidity in the stock as no one could buy a decent line of stock. Another reason could be the Phase 3 registrational trials can last between 1-4 years,so this really is the ’long game’.

User Image webroom Posted - 1 week ago

$VIR One hour of trading and they cannot bring It down, so there is only one way

User Image PCIntern Posted - 1 week ago

$VIR develops cure for all cancers and heart disease, share price plummets and placed on pink sheets. 🤯

User Image rispi Posted - 1 week ago

$VIR comm'on let's gimme 7.01

User Image rispi Posted - 1 week ago

$VIR today, after years, I'm on the BID side of the moon

User Image Cytomight Posted - 1 week ago

$VIR $CYDY YES VIR‼️ https://finance.yahoo.com/news/vir-biotechnology-receives-fda-breakthrough-210500608.html

User Image OpenOutcrier Posted - 1 week ago

$VIR (+2.3% pre) Vir Biotechnology (VIR) Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta - SI https://ooc.bz/l/50762

User Image Dunnieboy1 Posted - 1 week ago

$VIR i wonder at what point Vir captures the attention of investors, Janux Therapies soared last week 60/70% in after hours trading which followed through into the market opening the following day based on positive ’PHASE 1 TRIALS’. We have just announced tonight we have been approved for ’Prime Designation’ for our drugs in the USA(FDA) & Europe(EMA) & are registering for ’PHASE 3 TRIALS’ & are up only 6% after hours. It just seems we are getting by & large ignored even though our therapies & trials are much further advanced than Janux as a example. Perhaps the board are ’under promising to hopefully over deliver’.

User Image Dunnieboy1 Posted - 1 week ago

$VIR everything is going in the right direction except the share prices, remember the directors are charged with running the company not the day to day movements of the share price. Remember the saying ’build it & they will come’.

User Image VIR_Tical1 Posted - 1 week ago

$VIR glimmer of

User Image rispi Posted - 1 week ago

$VIR pretty good news

User Image Bangerplays Posted - 1 week ago

$VIR eyes coming in here

User Image Mhand Posted - 1 week ago

$VIR Just in time to get us back above $7.50. https://investors.vir.bio/news/news-details/2024/Vir-Biotechnology-Receives-FDA-Breakthrough-Therapy-Designation-and-EMA-PRIME-Designation-for-Tobevibart-and-Elebsiran-in-Chronic-Hepatitis-Delta/default.aspx

User Image Dunnieboy1 Posted - 1 week ago

$VIR marked down over 3% at the open, games not straight.

User Image Dunnieboy1 Posted - 1 week ago

$VIR bounce or more pain, all eyes on Jan 8 but we live in hope of a announcement prior to then & you never know there may be one.

User Image sittingonagoldmine Posted - 1 week ago

$VIR P/B ratio now at approx 0.90, still trading below book value despite very promising pipeline !

User Image Dunnieboy1 Posted - 1 week ago

$VIR still believing, still not selling & still wished i’d never set eyes on Vir😂😂😂

User Image Dunnieboy1 Posted - 1 week ago

$VIR i was thinking before about the Sanofi deal, we laid out a total of $175m & employed 50 of their management & scientists as part of the deal. So to pay & incentivise the employees then surely at some time soon then Vir will have to do either a ’new share issue’ or issue ’share options’ for the new employees, possibly they could utilise the ’mixed shelf offering’ which was passed last year as that allows for ’shares, options, warrants’ to be issued, Vir have 3yrs to utilise the ’mixed shelf offering’ from November 2023 & to my knowledge it hasn’t been utilised yet. I know this creates dilution but this is the way ‘growth companies’ grow. Anyway just thinking out loud!

User Image Steve_382 Posted - 2 weeks ago

$VIR Pretty weak close for no apparent reason today. Still looks like nothing happening until Jan. 8 probably.

User Image Dunnieboy1 Posted - 2 weeks ago

$VIR can we get over $9 today? Lets hope so, hopefully we don’t give up the 9% gains made since Friday & then we may see some buyers coming in.

User Image Winning_calls Posted - 2 weeks ago

$VIR 🤗🤗🤗

Analyst Ratings
HC Wainwright & Co. Buy Aug 20, 24
Barclays Overweight Aug 2, 24
Morgan Stanley Equal-Weight Jun 6, 24
HC Wainwright & Co. Buy Jun 5, 24
Needham Buy Jun 5, 24
HC Wainwright & Co. Buy May 24, 24
HC Wainwright & Co. Buy May 7, 24
JP Morgan Neutral May 3, 24
Needham Buy May 3, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Pang Phillip EVP & Chief Medical.. EVP & Chief Medical Officer Jan 02 Option 1.32 80,000 105,600 268,000 01/03/24
SVF Endurance (Cayman) Ltd 10% Owner 10% Owner Jun 30 Sell 25.11 700 17,577 16,684,041 07/05/23
SVF Endurance (Cayman) Ltd 10% Owner 10% Owner Jun 28 Sell 25.14 96,952 2,437,373 16,684,741 06/30/23
SVF Endurance (Cayman) Ltd 10% Owner 10% Owner Jun 20 Sell 25.1769 9,902 249,302 16,781,693 06/22/23
SVF Endurance (Cayman) Ltd 10% Owner 10% Owner Jun 15 Sell 25.83 183,326 4,735,311 16,791,595 06/20/23
SVF Endurance (Cayman) Ltd 10% Owner 10% Owner Jun 13 Sell 26.55 164,102 4,356,908 16,974,921 06/15/23
SVF Endurance (Cayman) Ltd 10% Owner 10% Owner Jun 02 Sell 27.32 39,562 1,080,834 17,139,023 06/06/23
SVF Endurance (Cayman) Ltd 10% Owner 10% Owner May 23 Sell 26.45 274,451 7,259,229 17,178,585 05/25/23
SVF Endurance (Cayman) Ltd 10% Owner 10% Owner May 19 Sell 25.55 183,547 4,689,626 17,453,036 05/23/23
SVF Endurance (Cayman) Ltd 10% Owner 10% Owner May 05 Sell 25.1032 136 3,414 17,636,583 05/09/23
SVF Endurance (Cayman) Ltd 10% Owner 10% Owner May 03 Sell 25.53 198,006 5,055,093 17,636,719 05/05/23
SVF Endurance (Cayman) Ltd 10% Owner 10% Owner May 01 Sell 25.3047 3,075 77,812 17,834,725 05/03/23
SVF Endurance (Cayman) Ltd 10% Owner 10% Owner Apr 24 Sell 25.36 66,999 1,699,095 17,837,800 04/26/23
SVF Endurance (Cayman) Ltd 10% Owner 10% Owner Apr 20 Sell 25.61 311,983 7,989,885 17,904,799 04/24/23
SVF Endurance (Cayman) Ltd 10% Owner 10% Owner Apr 18 Sell 25.12 83,067 2,086,643 18,216,782 04/20/23
SVF Endurance (Cayman) Ltd 10% Owner 10% Owner Apr 14 Sell 25.08 20,089 503,832 18,299,849 04/18/23
Friedl-Naderer Johanna EVP & Chief Operatin.. EVP & Chief Operating Officer Mar 03 Sell 22.82 1,482 33,819 148,518 03/07/23
Pang Phillip Chief Medical Office.. Chief Medical Officer Feb 22 Sell 25.97 2,878 74,742 198,320 02/24/23
Rice Steven J. Chief Administrative.. Chief Administrative Officer Feb 22 Sell 25.97 1,795 46,616 108,414 02/24/23
SVF Endurance (Cayman) Ltd 10% Owner 10% Owner Feb 21 Sell 28.01 74,477 2,086,101 18,319,938 02/23/23
SCANGOS GEORGE A President and CEO President and CEO Feb 17 Sell 27.37 27,750 759,518 196,239 02/21/23
Rice Steven J. Chief Administrative.. Chief Administrative Officer Feb 17 Sell 25.288 1,981 50,096 37,209 02/21/23
Pang Phillip Chief Medical Office.. Chief Medical Officer Feb 17 Sell 25.288 2,802 70,857 141,198 02/21/23
Horn Howard CFO CFO Feb 17 Sell 25.288 2,424 61,298 232,960 02/21/23
SVF Endurance (Cayman) Ltd 10% Owner 10% Owner Feb 15 Sell 26.7525 38,964 1,042,384 18,394,415 02/17/23
SVF Endurance (Cayman) Ltd 10% Owner 10% Owner Feb 13 Sell 26.24 117,957 3,095,192 18,433,379 02/15/23
SVF Endurance (Cayman) Ltd 10% Owner 10% Owner Feb 09 Sell 26.32 234,271 6,166,013 18,551,336 02/13/23
SVF Endurance (Cayman) Ltd 10% Owner 10% Owner Feb 07 Sell 28.58 145,422 4,156,161 18,785,607 02/09/23
SATO VICKI L Director Director Feb 08 Sell 28.68 17,915 513,802 1,345,259 02/09/23
SVF Endurance (Cayman) Ltd 10% Owner 10% Owner Feb 03 Sell 30.06 114,035 3,427,892 18,931,029 02/07/23
SVF Endurance (Cayman) Ltd 10% Owner 10% Owner Feb 01 Sell 29.22 148,635 4,343,115 19,045,064 02/03/23
SVF Endurance (Cayman) Ltd 10% Owner 10% Owner Jan 30 Sell 29.48 152,813 4,504,927 19,193,699 02/01/23
SVF Endurance (Cayman) Ltd 10% Owner 10% Owner Jan 23 Sell 28.13 36,512 1,027,083 19,346,512 01/25/23
Pang Phillip Chief Medical Office.. Chief Medical Officer Jan 24 Sell 30 30,000 900,000 144,000 01/25/23
SVF Endurance (Cayman) Ltd 10% Owner 10% Owner Jan 19 Sell 26.73 214,197 5,725,486 19,383,024 01/23/23
SVF Endurance (Cayman) Ltd 10% Owner 10% Owner Jan 17 Sell 26.28 190,839 5,015,249 19,597,221 01/19/23
SVF Endurance (Cayman) Ltd 10% Owner 10% Owner Jan 12 Sell 26.36 211,678 5,579,832 19,788,060 01/17/23
SVF Endurance (Cayman) Ltd 10% Owner 10% Owner Jan 10 Sell 26.19 149,640 3,919,072 19,999,738 01/12/23
SATO VICKI L Director Director Jan 09 Sell 25.8322 17,915 462,784 1,363,174 01/11/23
SVF Endurance (Cayman) Ltd 10% Owner 10% Owner Jan 06 Sell 25.97 100,980 2,622,451 20,149,378 01/10/23
SVF Endurance (Cayman) Ltd 10% Owner 10% Owner Jan 03 Sell 25.52 9,177 234,197 20,250,358 01/05/23
Sigal Charles Elliott Director Director Jan 03 Buy 25.43 5,000 127,150 5,000 01/05/23
SVF Endurance (Cayman) Ltd 10% Owner 10% Owner Dec 29 Sell 25.5487 44,169 1,128,461 20,259,535 01/03/23
SVF Endurance (Cayman) Ltd 10% Owner 10% Owner Dec 27 Sell 25.5918 6,850 175,304 20,303,704 12/29/22
SVF Endurance (Cayman) Ltd 10% Owner 10% Owner Dec 22 Sell 25.96 175,225 4,548,841 20,310,554 12/27/22
SVF Endurance (Cayman) Ltd 10% Owner 10% Owner Dec 20 Sell 25.83 215,756 5,572,977 20,485,779 12/22/22
SATO VICKI L Director Director Dec 08 Sell 25.8089 17,915 462,366 1,381,089 12/09/22
SVF Endurance (Cayman) Ltd 10% Owner 10% Owner Dec 02 Sell 27.36 97,293 2,661,936 20,701,535 12/06/22
SVF Endurance (Cayman) Ltd 10% Owner 10% Owner Nov 30 Sell 27.82 212,329 5,906,993 20,798,828 12/02/22
SVF Endurance (Cayman) Ltd 10% Owner 10% Owner Nov 28 Sell 27.62 109,115 3,013,756 21,011,157 11/30/22